To examine whether the target of acalabrutinib, BTK, was activated in patients with COVID-19, we studied BTK autophosphorylation at residue Y223 in whole blood samples from 3 patients with severe COVID-19 (Table S10) and in 5 healthy volunteers (Fig. S1). Here, BTK is linked to COVID-19.